All Phenotypes Ifit2<tm1.1Ebsb> MGI Mouse

Phenotypes associated with this allele

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Ifit2^tm1.1Ebsb/Ifit2^tm1.1Ebsb	B6.129P2(C)-Ifit2^tm1.1Ebsb	MGI:6272769
hm2	Ifit2^tm1.1Ebsb/Ifit2^tm1.1Ebsb	B6NCrl.129P2(C)-Ifit2^tm1.1Ebsb	MGI:5505706

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

increased IgE level ( J:233986 )

• plasma IgE levels are increased following ovalbumin (OVA) sensitization and repeated OVA airway challenge

increased IgG1 level ( J:233986 )

• plasma IgG1 levels are increased following OVA sensitization and repeated OVA airway challenge

increased IgG3 level ( J:233986 )

• plasma IgG3 levels are increased following OVA sensitization and repeated OVA airway challenge

increased IgM level ( J:233986 )

• plasma IgM levels are increased following OVA sensitization and repeated OVA airway challenge

immune system

increased IgE level ( J:233986 )

• plasma IgE levels are increased following ovalbumin (OVA) sensitization and repeated OVA airway challenge

increased IgG1 level ( J:233986 )

• plasma IgG1 levels are increased following OVA sensitization and repeated OVA airway challenge

increased IgG3 level ( J:233986 )

• plasma IgG3 levels are increased following OVA sensitization and repeated OVA airway challenge

increased IgM level ( J:233986 )

• plasma IgM levels are increased following OVA sensitization and repeated OVA airway challenge

enhanced humoral immune response ( J:233986 )

• mice show increased IgE, IgG1, IgG3, and IgM levels following OVA sensitization and repeated OVA airway challenge

• a slight increase of CD3+ cells and the Ly6c+ fraction from the CD4+ T cells is seen following OVA sensitization and repeated OVA airway challenge

• however, neither B cells nor T cells show differences in activation or proliferation under unchallenged cell culture conditions

Allelic Composition	Ifit2^tm1.1Ebsb/Ifit2^tm1.1Ebsb
Genetic Background	B6NCrl.129P2(C)-Ifit2^tm1.1Ebsb

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Ifit2^tm1.1Ebsb mutation (0 available); any Ifit2 mutation (26 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

increased susceptibility to bacterial infection induced morbidity/mortality ( J:199862 )

• most mice treated with LPS die unlike control mice

immune system

decreased circulating interleukin-1 beta level ( J:199862 )

• in LPS-treated mice after 6 and 12 hours

decreased circulating interleukin-12b level ( J:199862 )

• in LPS-treated mice after 6 hours

decreased circulating interleukin-6 level ( J:199862 )

• in LPS-treated mice after 6 hours

decreased circulating tumor necrosis factor level ( J:199862 )

• in LPS-treated mice after 6 and 12 hours

decreased interleukin-6 secretion ( J:199862 )

• from bone marrow-derived macrophage stimulated with LPS or E. coli K1 E-R8

decreased tumor necrosis factor secretion ( J:199862 )

• from bone marrow-derived macrophage stimulated with LPS or E. coli K1 E-R8

increased susceptibility to bacterial infection induced morbidity/mortality ( J:199862 )

• most mice treated with LPS die unlike control mice

homeostasis/metabolism

decreased circulating interleukin-1 beta level ( J:199862 )

• in LPS-treated mice after 6 and 12 hours

decreased circulating interleukin-12b level ( J:199862 )

• in LPS-treated mice after 6 hours

decreased circulating interleukin-6 level ( J:199862 )

• in LPS-treated mice after 6 hours

decreased circulating tumor necrosis factor level ( J:199862 )

• in LPS-treated mice after 6 and 12 hours

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 05/07/2024 MGI 6.23